The JAK1/2 inhibitor ruxolitinib has proven highly effective in a child with USP18 deficiency by combination with supportive therapy, achieving prolonged survival and resolution of the associated complications, albeit with slower progress in developmental milestones (11). Here, JAK1 is linked to hyperinsulinemic hypoglycemia, familial, 4.